In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Long-term benefits of cardiac rehabilitation in patients with diabetes mellitus after percutaneous coronary intervention

Session Poster Session 1

Speaker Maria Jose Romero Reyes

Event : ESC Congress 2019

  • Topic : preventive cardiology
  • Sub-topic : Rehabilitation: Outcomes
  • Session type : Poster Session

Authors : M J Romero Reyes (Seville,ES), R Rodriguez Delgado (Seville,ES), I Esteve Ruiz (Seville,ES), C Otte Alba (Seville,ES), JA Mora Pardo (Seville,ES), FJ Molano Casimiro (Seville,ES)

M J Romero Reyes1 , R Rodriguez Delgado1 , I Esteve Ruiz1 , C Otte Alba1 , JA Mora Pardo1 , FJ Molano Casimiro1 , 1University Hospital Virgen de Valme, Cardiology - Seville - Spain ,


Introduction: After percutaneous coronary intervention (PCI), patients with diabetes have a worse prognosis than non-diabetics and are at increased risk of recurrent cardiovascular events, hospitalization and higher mortality.
Purpose: The aim of our study was to evaluate the impact of cardiac rehabilitation (CR) in this high-risk group of patients. 
Methods: We performed a retrospective cohort study of 318 consecutive patients with type 2 diabetes mellitus (DM2) who underwent PCI in our hospital between 2004 and 2011. We classi?ed the patients in two cohorts according to their participation (n=154) or not (n=164) in a CR programme. We collected the events ocurring during a median follow-up of 9 years. 
Results: Using multivariate logistic regression, we found that CR participation was associated with significantly reduced all-cause mortality (53% vs 23%, OR 2,10; IC 95%; 1,16 - 3,82; p 0,014) and cardiac mortality (3,9% vs 23,8%, OR 8,69; IC95% 2,80-26,99; p < 0,0005). CR aslo associated with a singnificant decrease in a heart failure hospitalization  (26,6% vs 10,6%, OR 2,4; IC 95% 1,06- 5,52; p < 0,035). No signi?cant differences were observed in non fatal myocardial infarction, stent restenosis and non fatal stroke.
Conclusion: CR participation after PCI is associated with lower all-cause mortality, cardiac mortality and heart failure hospitalization  rates in patients with DM2 during long-term follow-up.


(n= 153)

No Rehabilitation

(n= 164)

P vaule

Male sex

138 (86,4%)

100 (61,0%)


Age (years)

59 (38-74)

65 (47-74)



113 (73,9%)

111 (67,7%)



112 (73,7%)

115 (70,1%)


HbA1c ≥ 7%

88 (66,2%)

73 (64,6%)


Prior myocardial infarction

24 (15,6%)

32 (19,5%)


Chronic kidney disease

6 (3,9%)

19 (11,6%)


FEVI < 50%

30 (20%)

39 (25%)


Three vessel disease

53 (34,4%)

58 (35,4%)


Incomplete revascularization

80 (51,9%)

81 (49,4%)


Drug-eluting stent

110 (78,6%)

127 (80,4%)


Stent length

22,4 ± 11,9

24,6 ± 14,8


Stent diameter

2,7 ± 0,3

2,8 ± 0,4


Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are